Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan Versus Sacituzumab Govitecan+Pembrolizumab in Low-risk, Triple-negative Early Breast Cancer (ADAPT-TN-III)

NCT06081244 is registered in ClinicalTrials.gov with Women's Cancer Study Group GmbH as lead sponsor.

NCT NCT06081244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06081244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan Versus Sacituzumab Govitecan+Pembrolizumab in Low-risk, Triple-negative Early Breast Cancer (ADAPT-TN-III)
Lead sponsor
Women's Cancer Study Group GmbH
Phase
Phase 3
Overall status
Recruiting
Start date
October 10, 2024
Completion date
September 30, 2029
Enrollment
348 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer